Amgen submits U.S. application to sell cholesterol-fighting drug

(Reuters) - Amgen Inc said it submitted an application to the U.S. Food and Drug Administration to market its cholesterol-lowering drug, evolocumab. The injectable drug works by blocking PCSK9, a naturally occurring protein that keeps "bad" LDL cholesterol levels elevated in the bloodstream. Other drugmakers, including Pfizer Inc, and a partnership between Regeneron Inc and Sanofi SA, are racing with Amgen to market potentially lucrative anti-PCSK9 antibodies. (Reporting by Natalie Grover in Bangalore; Editing by Maju Samuel)



via Health News Headlines - Yahoo News http://ift.tt/1mXc91Q